The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma

Center for Vascular Pathology, Moscow1,000 enrolled

Overview

Spinal hemangioma is one of the most common benign vertebral tumours. Being mostly asymptomatic, it is still associated with a pain syndrome especially if encroaches into the neural canal. This study is organised to evaluate the efficacy and safety of β-blockers drugs in adults with spinal hemangioma.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

1,000

Conditions

Spinal Tumor Spinal Hemangioma Beta Blocker Toxicity

Interventions

Atenolol PillDRUG

Atenolol is a second-generation hydrophilic β-1-selective adrenergic antagonist, which is primarily metabolised by the kidneys.

Propranolol PillDRUG

Propranolol is highly lipophilic, nonselective β-blockers, which is primarily metabolised by the liver.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * vertebral hemangioma Exclusion Criteria: * symptomatic bradycardia * AV block * decompensated heart failure * asthma

Locations (1)

The Vascular Anomalies Center (VAC) "Hemangioma"

Moscow, Russia

Outcomes

Primary Outcomes

Reducing tumor growth

MRI

Time frame: 3 months

Reducing tumor

MRI

Time frame: 6 months

Life-quality

Valid questionnaires based on the ones, approved by EuroQol Organization

Time frame: 3 months and 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.